A Study of LY3437943 in Participants With Type 2 Diabetes

  • STATUS
    Recruiting
  • End date
    Sep 30, 2022
  • participants needed
    300
  • sponsor
    Eli Lilly and Company
Updated on 25 November 2021
metformin
hemoglobin a1c

Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.

Details
Condition NIDDM, Diabetes Mellitus, type 2 diabetes mellitus, type 2 diabetes, type ii diabetes, noninsulin-dependent diabetes mellitus, diabetes type 2
Treatment Placebo, Dulaglutide, LY3437943
Clinical Study IdentifierNCT04867785
SponsorEli Lilly and Company
Last Modified on25 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Have Type 2 Diabetes (T2D)
Have an HbA1c value at screening of 7.0% and 10.5% and treated with diet and exercise alone or with a stable dose of metformin (either immediate release or extended release, 1000 milligram (mg)/day and not more than the locally approved dose) for at least 3 months prior to screening

Exclusion Criteria

Have type 1 diabetes mellitus (T1DM)
Have ketoacidosis
Have retinopathy, maculopathy
Have history of pancreatitis
Have obesity induced by other endocrine disorders
Have uncontrolled hypertension
Have acute or chronic hepatitis
Have chronic kidney disease
Have an autoimmune abnormality for example, lupus or rheumatoid arthritis
Have an active or untreated malignancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note